Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome

Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome

Show other versions (1)

Abstract Background Rett syndrome is a neuropediatric disease occurring due to mutations in MECP2 and characterized by a regression in the neuronal development following a normal postnatal growth, which results in the loss of acquired capabilities such as speech or purposeful usage of hands. While a...

Full description

Bibliographic Details
Main Authors: Uliana Musokhranova, Cristina Grau, Cristina Vergara, Laura Rodríguez-Pascau, Clara Xiol, Alba A. Castells, Soledad Alcántara, Pilar Rodríguez-Pombo, Pilar Pizcueta, Marc Martinell, Angels García-Cazorla, Alfonso Oyarzábal
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Journal of Translational Medicine
Subjects:
Rett syndrome
Metabolic modulation
Bioenergetics
Neuroinflammation
Leriglitazone
Mitochondria
Online Access:https://doi.org/10.1186/s12967-023-04622-5

Internet

https://doi.org/10.1186/s12967-023-04622-5

Similar Items